TP53 and acute myeloid leukemia: The longitudinal study of patients who developed t-MDS and t-AML suggests a pathogenetic mechanism based on the presence in these individuals of very minoritarian TP53 mutant clones of HSCs/HPCs that preferentially expanded after exposure to chemotherapy [80].